Dose-Ranging Study for Miconazole Oil for Treatment of Otomycosis

Otomycosis Clinical Trial

Official title:

Dose-Ranging Study of the Efficacy and Safety of Miconazole Oil Used for 7 or 14 Days Compared With Vehicle in the Treatment of Otomycosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03130738
• Other study ID #: HD-MCZ-PHII-DRF062016
• Status: Completed
• Phase: Phase 2
• Start date: April 20, 2017
• Est. completion date: August 6, 2019

Study information

• Verified date: September 2022
• Source: Hill Dermaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to evaluate the efficacy and safety of active treatment (miconazole oil) for 7 versus 14 days, and to compare 14 days of active treatment (miconazole oil) to inactive treatment (placebo) over a 14-day treatment duration, in subjects with fungal infection (otomycosis) of the external ear.

Description:

Miconazole, an imidazole antifungal agent, is commonly used for different types of fungal skin infections, such as Candida, ringworm, jock itch, athlete's foot, nail fungus, vaginal yeast infections, and oropharyngeal candidiasis. The 2% formulation of miconazole is commonly used for dermatophytic infections. The mechanisms of action of miconazole against fungi in general appear to be applicable to fungi associated with otomycosis, in that miconazole has been demonstrated to have activity in vitro against some clinical isolates of fungi associated with human otomycosis in the US.

Miconazole targets the cytochrome P450-dependent enzyme 14-α-sterol demethylase, an enzyme that is also involved in mammalian cholesterol synthesis, resulting in inhibition of ergosterol biosynthesis in the cell membrane of the fungal organism. Because ergosterol is an important component of the cell membrane, inhibition of its synthesis inhibits fungal cell growth.

In addition to its activity toward the enzyme 14-α-sterol demethylase, miconazole also leads to increased reactive oxygen species in fungal organisms, which appears to result in fungicidal activity.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 65
• Est. completion date: August 6, 2019
• Est. primary completion date: August 6, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 25 Months and older

Eligibility

Inclusion Criteria:

• Uncomplicated otomycosis of the external ear only, age more than 2 year

Exclusion Criteria:

• Pregnancy

• Other dermatoses or conditions of the ear that may interfere with the evaluation of otomycosis, including concomitant otic infections (including bacterial infection) that require antimicrobial treatment, disease that has spread beyond the external ear(s), or pre-existing skin atrophy of the affected ear(s)

• Tympanostomy tube or perforated tympanic membrane in the ear(s) that will be treated

• Previous surgery affecting the ear(s) that will be treated, except for prior tympanostomy tube(s) that had been removed and had completely healed

• Previous use of medicated treatments for otomycosis or participation in another investigational study within 28 days of study entry

• Previous use of any systemic antifungal therapy, warfarin, and immunosuppressive or immune-stimulating drugs within 28 days of study entry, or systemic steroids within 3 months of study entry

• Recurrent otomycosis that had been unresponsive to previous antifungal treatment

• Known hypersensitivity to any of the components in the test formulation

Related Conditions & MeSH terms

• Otomycosis

Intervention

Drug:
• 7-Day Miconazole Oil (Miconazole 2%)
7 days of 2x per day treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
• 14-Day Miconazole Oil (Miconazole 2%)
14 days of 2x per day treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
• 14-Day Placebo - Oil Vehicle
14 days of 2x per day treatment with Placebo - Oil Vehicle, Study Drug base without active ingredient

Locations

Country	Name	City	State
United States	Ear Nose and Throat Associates of Southe Florida	Boynton Beach	Florida
United States	Head and Neck Surgery Specialist	Chula Vista	California
United States	University of California San Diego	La Jolla	California
United States	Advanced ENT and Allergy	Louisville	Kentucky
United States	Silverstein Institute	Sarasota	Florida
United States	Piedmont ENT Associates	Winston-Salem	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
Hill Dermaceuticals, Inc.	QST Consultations, Ltd.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary Efficacy Endpoint	Percentage of subjects in MITT population, at the "Test of Cure" visit with "Therapeutic cure", defined as a negative fungal culture plus "clinical cure" defined as the absence of all otomycosis signs and symptoms for pruritus, debris, fungal elements, and pain.	At Test of Cure visit (Day 15 for 7 Day Active and Day 22 for 14 Day Active and 14 Day Vehicle)
Secondary	Secondary Efficacy Endpoints	Percentage of subjects in MITT population with clinical cure at the Test of Cure Visit; Percentage of subjects in MITT population with a negative fungal culture at the Test of Cure Visit; Percentage of subjects in MITT population with a negative fungal culture at the Test of Cure visit as well as individual sign or symptom score of 0 or 1 on each of the scales for pruritus and debris and a score of 0 on each of the scales for fungal elements and pain (Secondary therapeutic cure).; Percentage of subjects in MITT population with individual signs or symptoms with a score of 0 or 1 on each of the scales for pruritus and debris and a score of 0 on each of the scales for fungal elements and pain (Secondary clinical cure).	At Test of Cure visit (Day 15 for 7 Day Active and Day 22 for 14 Day Active and 14 Day Vehicle)